Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitleSafety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.AuthorsJoerger, Markus; Hundsberger, Thomas; Haefliger, Simon; von Moos, Roger; Hottinger, Andreas F.; Kaindl, Thomas; Engelhardt, Marc; Marszewska, Michalina; Lane, Heidi; Roth, Patrick; Stathis, AnastasiosPublicationInvestigational New Drugs, 2023, Vol 41, Issue 2, p267ISSN0167-6997Publication typeArticleDOI10.1007/s10637-023-01336-9